NASDAQ:PALI Palisade Bio (PALI) Stock Price, News & Analysis $1.87 -0.05 (-2.60%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$1.88 +0.00 (+0.27%) As of 05/13/2026 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Palisade Bio Stock (NASDAQ:PALI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Palisade Bio alerts:Sign Up Key Stats Today's Range$1.86▼$1.9650-Day Range$1.63▼$2.8052-Week Range$0.53▼$2.86Volume1.87 million shsAverage Volume4.26 million shsMarket Capitalization$313.08 millionP/E RatioN/ADividend YieldN/APrice Target$10.20Consensus RatingModerate Buy Company Overview Palisade Bio, Inc. is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity. The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors. Palisade Bio is also advancing a pipeline of next‐generation candidates designed to support combination approaches with checkpoint inhibitors, adoptive cell therapies and other standard‐of‐care modalities. The platform’s modular design enables the development of both injectable and implantable formats to address a variety of tumor types and anatomic locations. Palisade Bio operates out of facilities in the United States and collaborates with academic research centers, contract research organizations and biotechnology partners to accelerate its clinical programs. The company maintains a management team with extensive experience in oncology drug development, immunology and precision medicine. As it progresses through clinical milestones, Palisade Bio aims to validate its platform’s capacity to enhance anti‐tumor efficacy while reducing systemic immune‐related adverse events. AI Generated. May Contain Errors. Read More Palisade Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScorePALI MarketRank™: Palisade Bio scored higher than 36% of companies evaluated by MarketBeat, and ranked 725th out of 864 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingPalisade Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialPalisade Bio has a consensus price target of $10.20, representing about 445.5% upside from its current price of $1.87.Amount of Analyst CoveragePalisade Bio has only been the subject of 3 research reports in the past 90 days.Read more about Palisade Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Palisade Bio are expected to decrease in the coming year, from ($0.18) to ($0.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Palisade Bio is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Palisade Bio is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPalisade Bio has a P/B Ratio of 2.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.63% of the float of Palisade Bio has been sold short.Short Interest Ratio / Days to CoverPalisade Bio has a short interest ratio ("days to cover") of 5.21.Change versus previous monthShort interest in Palisade Bio has recently increased by 1.98%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPalisade Bio does not currently pay a dividend.Dividend GrowthPalisade Bio does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment-0.02 News SentimentPalisade Bio has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Palisade Bio this week, compared to 3 articles on an average week.Search InterestOnly 21 people have searched for PALI on MarketBeat in the last 30 days. This is a decrease of -5% compared to the previous 30 days.MarketBeat Follows5 people have added Palisade Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Palisade Bio insiders have not sold or bought any company stock.Percentage Held by Insiders0.07% of the stock of Palisade Bio is held by insiders.Percentage Held by Institutions11.79% of the stock of Palisade Bio is held by institutions.Read more about Palisade Bio's insider trading history. Receive PALI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palisade Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PALI Stock News HeadlinesPalisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108May 12 at 4:15 PM | globenewswire.comPalisade Bio, Inc. (NASDAQ:PALI) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 6, 2026 | americanbankingnews.comYour temporary download link is expiringBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. | Profits Run (Ad)Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative ColitisMay 5, 2026 | globenewswire.comPalisade Bio (PALI) price target decreased by 12.09% to 10.20April 29, 2026 | msn.comWolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical ProfileApril 17, 2026 | insidermonkey.comPalisade Bio, Inc. Announces Poster Presentation at Digestive Disease Week® 2026 Featuring PALI-2108 Data on Ulcerative ColitisApril 16, 2026 | quiverquant.comQPalisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026April 16, 2026 | globenewswire.comSee More Headlines PALI Stock Analysis - Frequently Asked Questions How have PALI shares performed this year? Palisade Bio's stock was trading at $2.35 at the beginning of the year. Since then, PALI stock has decreased by 20.4% and is now trading at $1.87. How were Palisade Bio's earnings last quarter? Palisade Bio, Inc. (NASDAQ:PALI) announced its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.01. When did Palisade Bio's stock split? Palisade Bio shares reverse split before market open on Monday, April 8th 2024.The 1-15 reverse split was announced on Monday, April 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Palisade Bio's major shareholders? Top institutional shareholders of Palisade Bio include Simplify Asset Management Inc. (0.21%). Insiders that own company stock include John David Finley, Mitchell Lawrence Jones, Donald Allen Williams and Robert J Trenschel. View institutional ownership trends. How do I buy shares of Palisade Bio? Shares of PALI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Palisade Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Palisade Bio investors own include Iterum Therapeutics (ITRM), Oncobiologics (OTLK), Bionano Genomics (BNGO), PayPal (PYPL) and Tesla (TSLA). Company Calendar Last Earnings5/12/2026Today5/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 PALI's financial health is in the Green zone, according to TradeSmith. PALI has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PALI CIK1357459 Webwww.palisadebio.com Phone(858) 704-4900FaxN/AEmployees10Year Founded2005Price Target and Rating Average Price Target for Palisade Bio$10.20 High Price Target$25.00 Low Price Target$5.00 Potential Upside/Downside+445.5%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($2.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$16.78 million Net MarginsN/A Pretax MarginN/A Return on Equity-53.59% Return on Assets-48.96% Debt Debt-to-Equity RatioN/A Current Ratio28.95 Quick Ratio28.95 Sales & Book Value Annual Sales$250 thousand Price / Sales1,252.30 Cash FlowN/A Price / Cash FlowN/A Book Value$0.87 per share Price / Book2.15Miscellaneous Outstanding Shares167,420,000Free Float167,307,000Market Cap$313.08 million OptionableNot Optionable Beta1.52 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:PALI) was last updated on 5/14/2026 by MarketBeat.com Staff. From Our PartnersIs this AI lab Elon’s SpaceX lifeline?Elon Musk went from calling one AI lab 'evil' to striking a deal giving it access to SpaceX's entire Colossus ...Chaikin Analytics | SponsoredThe one number Musk can't hide in the S-1When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...Behind the Markets | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredCollect $1,170 a month from silverI've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...Investors Alley | SponsoredThe system holding the dollar together is gone…Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredStarting This July: Hundreds of trillions of dollars at stakeAccording to The Wall Street Journal, a new wave of asset tokenization is sweeping global markets - and it cou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palisade Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
